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Abstract
Background: Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease
with heterogeneous clinical outcomes. Several molecular classifications have been
proposed, but the diversity of their subtype sets impedes their clinical application.
Objective: To achieve an international consensus on MIBC molecular subtypes that
reconciles the published classiﬁcation schemes.
Design, setting, and participants: We used 1750 MIBC transcriptomic proﬁles from
16 published datasets and two additional cohorts.
Outcome measurements and statistical analysis: We performed a network-based anal-
ysis of six independent MIBC classiﬁcation systems to identify a consensus set of
molecular classes. Association with survival was assessed using multivariable Cox
models.
Results and limitations: We report the results of an international effort to reach a
consensus on MIBC molecular subtypes. We identiﬁed a consensus set of six molecular
classes: luminal papillary (24%), luminal nonspeciﬁed (8%), luminal unstable (15%),
stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consen-
sus classes differ regarding underlying oncogenic mechanisms, inﬁltration by immune
and stromal cells, and histological and clinical characteristics, including outcomes. We
provide a single-sample classiﬁer that assigns a consensus class label to a tumor sample’s
transcriptome. Limitations of the work are retrospective clinical data collection and a
lack of complete information regarding patient treatment.
Conclusions: This consensus system offers a robust framework that will enable testing
and validation of predictive biomarkers in future prospective clinical trials.
Patient summary: Bladder cancers are heterogeneous at the molecular level, and
scientists have proposed several classiﬁcations into sets of molecular classes. While
these classiﬁcations may be useful to stratify patients for prognosis or response to
treatment, a consensus classiﬁcation would facilitate the clinical use of molecular
classes. Conducted by multidisciplinary expert teams in the ﬁeld, this study proposes
such a consensus and provides a tool for applying the consensus classiﬁcation in the
clinical setting.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Bladdercancer is one of the most frequently diagnosed cancers
in North America and Europe. Most bladder cancers are
urothelial carcinomas, and are classified as either non–
muscle-invasive bladder cancer (NMIBC) or muscle-invasive
bladder cancer (MIBC), due to distinct implications for patient
management. MIBC is usually diagnosed de novo but may arise
from the 10–20% of NMIBC cases that eventually progress.
MIBC is a more aggressive disease state, and is associated with
a 5-yr survival rate of 60% for patients with localized disease
and <10% for patients with distant metastases.
At the molecular level, MIBC is a heterogeneous disease
that is characterized by genomic instability and a high
mutation rate. Transcriptome profiling facilitates bladder
cancer classification into molecular subtypes, for a more
precise patient stratification according to prognosis and
therapeutic options. A number of teams have reported
molecular classifications of bladder cancers. Several ex-
pression-based schemes have been proposed, either con-
sidering the full spectrum of nonmetastatic bladder cancers
[1–6], or focusing separately either on NMIBC [7,8] or on
MIBC [9–16]. These classifications have considerably
advanced our understanding of bladder cancer biology.
Specific genomic alterations are enriched in particularPlease cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006molecular subtypes, including mutations targeting genes
involved in cell cycle regulation, chromatin remodeling, and
receptor tyrosine kinase signaling. Importantly, several
reports have highlighted the clinical significance of
molecular stratification of MIBC, by suggesting that
responses to chemotherapy and immunotherapy may be
enriched in specific MIBC subtypes [12,17–19].
Published MIBC classifications were derived from largely
nonoverlapping datasets, using different methods at least
for some steps of their respective unsupervised class
discovery pipelines (Supplementary Table 1). Nonetheless,
they share many characteristics, including subtype-specific
molecular features, and a strong overlap has been observed
between some subtypes from distinct classification systems
[20]. In an initial effort to define features common to all
MIBC classifications, Lerner et al. [21] proposed a consensus
basal/squamous subtype and reported evidence of a
muscle-invasive subtype with urothelial differentiation
features. However, the six published classification systems
that were considered in their work still differ in the number
and relative size of subtypes, and in the use of different
subtype names. This diversity has impeded transferring
subtypes into clinical practice and highlights that establish-
ing a single consensus set of molecular subtypes would
facilitate achieving such a transfer.ssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
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2.1. Transcriptomic profiles analyzed
We used 1750 MIBC transcriptomic profiles from 18 datasets
to compare six molecular classification schemes and derive
a consensus classification. Details of datasets, including
their respective normalizations, are given in Supplementary
Table 2.
2.2. Consensus classification construction
Transcriptomic classifiers for six published classification
systems [9–13,16] were provided and/or validated by the
respective teams. These classifiers were merged into an R
package (R Foundation for Statistical Computing, Vienna,
Austria) that is documented and freely available at https://
github.com/cit-bioinfo/BLCAsubtyping.
We applied these classifiers on each of the 18 datasets
independently to assign each sample to a subtype in each
of the six classification systems. We used a previously
validated network-based approach [22] on these subtyp-
ing results to identify consensus classes that reconcile the
molecular subtypes from the six classification schemes.
Briefly, we built a weighted network of subtyping results,
using Cohen’s kappa metric to quantify similarities
between subtypes from different classification systems,
and applied a Markov cluster algorithm to identify robust
network substructures corresponding to potential con-
sensus classes. The analysis workflow is summarized in
Supplementary Fig. 1 and algorithm details are given in
the Supplementary material (Methods). We used a
silhouette-based metric to select the most robust
consensus solution among those with consensus classes
defined by at least three of the six input classification
systems.
2.3. Single-sample transcriptomic consensus classifier
construction
The network of consensus classes also revealed a core set of
consensus samples (see Supplementary material, Methods),
that is, tumor samples representative of each consensus
class on the basis of their initial subtyping by the six
classification systems. We used these core samples (-
n = 1084) to build a single-sample transcriptomic classifier,
as detailed in the Supplementary material (Methods). The
classifier was trained on approximately one-third of these
samples (n = 403) and achieved 97% mean balanced
accuracy on the remaining two-thirds of the core samples
(n = 681). This classification tool was implemented as an R
package that is documented and freely available at https://
github.com/cit-bioinfo/consensusMIBC.
We also offer a stand-alone web application that allows
users to classify new samples using the single-sample
classifier. By design, it does not store any user data and can
be used completely anonymously. The consensusMIBC web
application is available at http://cit.ligue-cancer.net:3838/
apps/consensusMIBC_web/Please cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.0062.4. Statistical analyses
We measured associations between consensus classes and
categorical variables by Fisher’s exact tests, with Monte-Carlo
simulations when necessary. For continuous variables, we
evaluated differences by Kruskal-Wallis tests or LIMMA
moderated t tests (limma v3.39.1 R package). False discovery
rate adjustment of p values was performed to control for
multiple testing, for association tests between the consensus
classes and either genetic or histological variables, as these
types of variables might be interpreted as potential
diagnostic or theranostic biomarkers of some consensus
classes. We reported unadjusted p values otherwise.
We built a multivariable Cox model integrating consen-
sus classes and clinical risk factors. We used Wald tests to
assess survival differences associated with different levels
of a given factor included in the Cox model. For each factor
level, we computed hazard ratios (HRs) and 95% confidence
intervals (CIs). We constructed Kaplan-Meier curves to
visualize overall survival stratified by consensus class and
used log-rank tests to compare the survival of correspond-
ing patient groups.
All statistical and bioinformatics analyses were per-
formed with R (v3.5.1).
3. Results
3.1. Published molecular classifications of MIBC converge on six
classes
We used six published MIBC molecular classifications to
define a unified consensus subtyping system, following the
approach outlined in Supplementary Fig. 1 and described in
the Supplementary material (Methods). We refer to these
input classifications as Baylor [16], University of North
Carolina (UNC) [10], MD Anderson Cancer Center (MDA) [12],
the Cancer Genome Atlas (TCGA) [9], Cartes d’Identité des
Tumeurs (CIT)-Curie [11], and Lund [13]. The methods that
defined these classifications are summarized in the Supple-
mentary material (Methods) and Supplementary Table 1.
Our analysis converged on six biologically relevant
consensus molecular classes, which we labeled as luminal
papillary (LumP), luminal nonspecified (LumNS), luminal
unstable (LumU), stroma-rich, basal/squamous (Ba/Sq), and
neuroendocrine-like (NE-like; Fig. 1). Considerations moti-
vating our choices for these consensus names are detailed in
the Supplementary material (Note).
The six molecular classes had variable sample sizes, with
Ba/Sq and LumP being the largest (35% and 24% of all samples,
respectively). The remaining 41% of samples were LumU
(15%), stroma-rich (15%), LumNS (8%), and NE-like (3%)
tumors (Fig. 1B). The consensus classification was strongly
associated with each of the initial classification systems
(Fisher simulated p < 0.001;Fig.1 and Supplementary Fig. 2A).
We compared the consensus classes with the TCGA
PanCancer Atlas integrative classification [23] (Supplemen-
tary Fig. 2C). We observed associations between the Ba/Sq
consensus class and the squamous cell carcinoma C27:Pan-
SCC pan-cancer cluster (p < 0.001), and between thessiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
Fig. 1 – The six consensus classes and their relationships to input molecular subtypes. (A) MCL-clustered network. The six-consensus class solution obtained
with MCL clustering on the Cohen’s kappa-weighted network is represented by the six cliques surrounded by black dotted rectangles (see the
Supplementary material [Note] for the naming of consensus classes). The circles inside each clique symbolize the input subtypes associated with each
consensus class and are colored according to their matching classification system. Circle size is proportional to the number of samples assigned to the
subtype. Edge width between subtypes is proportional to the Cohen’s kappa score, which assesses the level of agreement between two classification
schemes. (B) Input subtypes repartitioned among each consensus class. Consensus classes were predicted on 1750 MIBC samples using the single-sample
classifier described in the Supplementary material (Methods). Here, the samples are grouped by their predicted consensus class labels: LumP, LumNS, LumU,
stroma-rich, Ba/Sq, and neuroendocrine (NE)-like. For each consensus class, a bar plot shows the proportion of samples assigned in each input subtype of
each input classification system. See also Supplementary Fig. 2 for additional visualization of consensus class distributions across input subtypes and across
datasets. (C) Relationship between subtyping results from the six input classification schemes. Samples are ordered by predicted consensus classes.
Ba/Sq = basal/squamous; LumNS = luminal nonspecified; LumP = luminal papillary; LumU = luminal unstable; MCL = Markov cluster algorithm; MDA = MD
Anderson Cancer Center; MIBC = muscle-invasive bladder cancer; TCGA = the Cancer Genome Atlas; UNC = University of North Carolina.
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(stromal/immune) pan-cancer cluster (p < 0.001).
3.2. Transcriptomic characterization of the six consensus
molecular classes
We used mRNA data from all 1750 samples to characterize
consensus classes with molecular gene signatures forPlease cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006bladder cancer pathways and for tumor microenvironment
infiltration (Fig. 2A and B, and Supplementary Table 3).
Differentiation-related mRNA signatures were strongly
associated with the consensus classes. Tumors from the
three luminal classes overexpressed urothelial differentia-
tion signatures (p < 0.001), including the PPARG/GATA3/
FOXA1-related Lund signature [24]. In contrast, Ba/Sq and
NE-like tumors, respectively, overexpressed gene signaturesssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
Fig. 2 – Characterization of tumor and stroma signals using published mRNA signatures and regulon analysis. Descriptions of gene sets and detailed
statistics are available in Supplementary Table 3. (A) We performed a gene set analysis (GSA; see the Supplementary material, Methods) in each dataset
to test the significance of differential expression of specific bladder cancer–related signatures in each consensus class compared with the others. The
heatmaps show Stouffer combined GSA p values over all datasets. The upper panel refers to bladder cancer gene sets extracted from the ICA
components described in the study by Biton et al. [25] (see the Supplementary material, Methods). The lower panel displays other bladder cancer–
specific signatures retrieved from the literature: urothelial differentiation, keratinization, and late cell-cycle signatures from the study of Eriksson
et al. [24], and an FGFR3 coexpressed signature from the study of Sjödahl et al. [4]. (B) We used two mRNA-based computational tools to characterize
tumor microenvironments : ESTIMATE (R package, v1.1.0) infers the presence of stromal cells (stromal infiltration) and the infiltration of immune cells
(immune infiltration) in a tumor sample using two curated gene signatures described by Yoshihara et al. [26]; MCPcounter (R package, v1.0.13) uses
biologically validated transcriptomic markers of specific immune and stromal cell subpopulations to quantify the presence of these populations in a
tumor sample [27]. We ran MCPcounter and ESTIMATE independently on each dataset, and used t tests to compare scores for each consensus class
relative to the others. The heatmaps show Stouffer combined t test p values over all datasets. (C) We computed discrete regulon status (1 for active
regulon status, 0 for undefined status, and –1 for inactive regulon status) in each dataset, as described in the Supplementary material (Methods) and
in the work of Robertson et al. [9]. We evaluated the association between each regulon status and each consensus class using Fisher exact tests; the
heatmap illustrates the resulting p values.
Ba/Sq = basal/squamous; ICA = independent component analysis; LumNS = luminal nonspecified; LumP = luminal papillary; LumU = luminal unstable;
NE = neuroendocrine; NK = natural killer.
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differentiation (p < 0.001), respectively.
In addition to their urothelial differentiation status, the
three luminal classes exhibited distinct molecular signa-
tures. LumP tumors were characterized by high expression
of a noninvasive Ta pathway signature [25] (p < 0.001) and
were strongly associated with FGFR3 transcriptional activi-
ty, as estimated by an FGFR3 coexpressed gene signature [4]Please cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006(p < 0.001). LumNS tumors displayed elevated stromal
infiltration signatures, mainly fibroblastic, compared with
the other luminal tumors (p < 0.001). LumU tumors had a
higher cell cycle activity than the other luminal tumors
(p < 0.001).
Stroma-rich samples displayed intermediate levels of
urothelial differentiation. They were mainly characterized
by stromal infiltration as summarized by ESTIMATE stromalssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
E U R O P E A N U R O L O G Y X X X ( 2 0 1 9 ) X X X – X X X6
EURURO-8567; No. of Pages 14scores [26], with overexpression of smooth muscle (-
p < 0.001), endothelial (p < 0.001), fibroblast (p < 0.001),
and myofibroblast (p < 0.001) gene signatures.
Immune infiltration was mainly found within Ba/Sq and
stroma-rich tumors, but these two classes were associated
with distinct immune cell populations, as estimated by
MCPcounter signatures [27]. Ba/Sq tumors were enriched in
cytotoxic lymphocytes (p < 0.001) and natural killer cells
(p < 0.001), whereas stroma-rich tumors overexpressed T-
(p < 0.001) and B-cell (p < 0.001) markers. LumNS tumors
were the only luminal type associated with immune
infiltration signals; these were mainly for B (p = 0.002)
and T (p = 0.004) lymphocytes. We detected no transcrip-
tomic markers of immune infiltration in NE-like tumors. In
TCGA samples, an estimation of tumor purity with
ABSOLUTE [28] confirmed that stroma-rich and Ba/Sq
tumors contained higher levels of nontumor cells (Supple-
mentary Fig. 3).
Analyses of regulatory units (ie, regulons) for 23 regulator
genes previously reported as associated with bladder cancer
[9] were consistent with the assessed mRNA signatures
(Fig. 2C). Luminal tumors, which overexpressed strong
urothelial differentiation signals, were associated with
active PPARG and GATA3 regulons (p < 0.001 for both
comparisons). FGFR3 regulon activity was specifically
associated with LumP tumors (p < 0.001), and Ba/Sq tumors
showed a strong association with STAT3 regulon activity
(p < 0.001), consistent with previous results [16,24].Fig. 3 – Genomic alterations associated with consensus classes. (A) We used th
association between consensus classes and specific gene mutations (see Supple
13 genes with MutSig q values <0.02 found in >10% of all tumors. Gene mutat
by an asterisk. (B) Combined genomic alterations associated with seven bladde
classes. Upper panels: main alteration types after aggregating CNA profiles (see
Stransky (n = 22), and TCGA (n = 404) data; exome profiles (n = 388) and FGFR3
MLPA data from CIT (n = 86 and n = 85, respectively) and Stransky (n = 16 and 
(n = 87), Iyer (n = 39), Sjödahl (n = 28), and Stransky (n = 35); TP53 mutation d
Stransky (n = 19); and RB1 mutation data from MDA (n = 66), CIT (n = 85), Iyer
consensus class, each type of gene alteration, and the combined alterations we
enriched with alterations of these candidate genes are marked with a black as
Ba/Sq = basal/squamous; CIT = Cartes d’Identité des Tumeurs; CNA = copy numbe
LumU = luminal unstable; MDA = MD Anderson Cancer Center; MIBC = muscle-in
Atlas.
Please cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006Additionally, a regulon analysis showed an association of
HIF1A regulon activity with Ba/Sq tumors (p < 0.001),
suggesting that this class is associated with a hypoxic
microenvironment. EGFR regulon activity was specifically
associated with Ba/Sq tumors (p < 0.001), consistent with
previously reported findings [11].
3.3. Genomic alterations associated with the consensus
molecular classes
We used TCGA exome data to identify class-specific
mutations (Fig. 3A and Supplementary Table 4) and
combined 600 available copy number profiles, grouped
by consensus class, to identify class-specific copy number
aberrations (CNAs; Supplementary Table 5). In addition, we
combined all CNA, gene fusion, and gene mutation data
from the 18 cohorts to generate comprehensive profiles of
genomic alterations for seven key bladder cancer genes
(FGFR3, CDKN2A, PPARG, ERBB2, E2F3, TP53, and RB1) for
each consensus class (Fig. 3B).
LumP tumors were mainly enriched in FGFR3 mutations,
with 33% of FGFR3-mutated LumP tumors in the TCGA
cohort (p-adjusted <0.001) and summing to 40% by adding
FGFR3-targeted sequencing mutation data (n = 255) from
additional cohorts (p-adjusted <0.001). LumP tumors also
harbored more frequent mutations of KDM6A (38%, p-
adjusted = 0.013). Assembling mutations, fusions, and copy
number amplifications, FGFR3 genomic alterations weree available exome data from 388 TCGA MIBC samples to study the
mentary Table 4 and Supplementary Fig. 3). The panel displays the
ions that were significantly enriched in one consensus class are marked
r cancer–associated genes and statistical association with consensus
 Supplementary Table 5) from CIT (n = 87), Iyer (n = 58), Sjödahl (n = 29),
 and PPARG fusion data (n = 404) from TCGA data; CDKN2A and RB1
n = 13, respectively) data; FGFR3 mutation data from MDA (n = 66), CIT
ata from MDA (n = 66), CIT (n = 87), Iyer (n = 39), Sjödahl (n = 28), and
 (n = 39), and Stransky (n = 13). Lower panels: associations between each
re evaluated by Fisher’s exact test. Consensus classes significantly
terisk.
r aberration; LumNS = luminal nonspecified; LumP = luminal papillary;
vasive bladder cancer; NE = neuroendocrine; TCGA = the Cancer Genome
ssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
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plex ligation-dependent probe amplification (MLPA) from
102 tumors and CNA data for 502 tumors revealed
homozygous/deep deletions of CDKN2A in 33% of LumP
tumors, which was significantly higher than in other classes
(p < 0.001). These deletions were consistent with the
enrichment of LumP tumors within the TCGA pan-cancer
iCluster C7:Mixed (Chr9 del) (p < 0.001), characterized by
chromosome 9 deletions (Supplementary Fig. 2).
The LumNS class was mainly characterized by enrich-
ment of mutations in ELF3 (35%, p-adjusted = 0.026), which
is an early regulator of urothelial differentiation and is
activated by PPARG [29]. PPARG was significantly altered as
well, with 76% of LumNS tumors harboring either ampli-
fications or fusions (p = 0.006).
LumU tumors also harbored frequent PPARG alterations
(89%, p < 0.001) and high-level amplifications of a 6p22.3
region that contains E2F3 and SOX4 (76%, p < 0.001). ERBB2
amplifications were over-represented in LumU tumors (39%,
p < 0.001), but no significant association was found between
ERBB2 mutations and any of the consensus classes. In contrast
with the other luminal classes, LumU tumors were associated
with mutations in TP53 (76%, p-adjusted <0.001) and in
ERCC2, which codes for a core nucleotide-excision repair
component (22%, p-adjusted = 0.039). More generally, LumU
was the most genomically altered class (Supplementary Fig.
3), displaying the highest number of CNAs (p < 0.001) and the
highest somatic mutation load (p = 0.009), and including
more APOBEC-induced mutations than the other consensus
classes (p = 0.01). These features of genomic instability and
the association with ERBB2 amplifications were consistent
with the enrichment of LumU tumors within the TCGA pan-
cancer subtypes C2:BRCA (HER2 amp) (breast tumors
characterized by frequent ERBB2 amplifications, p < 0.001)
and C13:Mixed (Chr8 del) (enriched in highly aneuploid
tumors, p < 0.001, as shown in Supplementary Fig. 2) [23].
For Ba/Sq tumors, as shown previously [30], the most
frequently mutated genes based on TCGA exome data were
TP53 (61%, p-adjusted = 0.002) and RB1 (25%, p-adjusted =
0.012). Aggregated mutation data, including targeted se-
quencing data from other cohorts, revealed that 58% (134/
232, p = 0.009) and 20% (43/224, p = 0.007) of Ba/Sq tumors
contained mutations in TP53 and RB1, respectively; these
mutations co-occurred in 14% (32/224) of Ba/Sq cases. Ba/Sq
tumors were also strongly associated with genomic deletions
of 3p14.2, which occurred in 49% of cases (p = 0.001).
Combining all available data on genomic alterations of
TP53 and RB1, we observed strong enrichment of concurrent
TP53 and RB1 inactivation in NE-like tumors. TP53 was
ubiquitously mutated in these tumors (94%, p-adjusted =
0.030), and co-occurred with RB1 alteration by either
mutations or deletions (94%, p-adjusted = 0.029).
3.4. Histological patterns associated with the consensus
molecular classes
To characterize the consensus molecular classes histologi-
cally, we assembled annotations for urothelial cancer
histological variants and specific morphological patternsPlease cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006(Fig. 4 and Supplementary Fig. 4). As expected, Ba/Sq tumors
included 79% of tumors in which histological review
identified squamous differentiation (126/159, p-adjusted
<0.001). However, the Ba/Sq class extended beyond this
histological subtype, with only 42% (126/303) of Ba/Sq
tumors being associated with squamous differentiation
identified by pathologists. Similarly, NE-like tumors were
strongly associated with neuroendocrine variant histology,
with 72% of histologically reviewed NE-like tumors showing
neuroendocrine differentiation (13/18, p-adjusted <0.001),
which accounts for 81% of all tumors with such differentia-
tion. LumP tumors were enriched with papillary morphol-
ogy as compared with other consensus classes (p-
adjusted = 0.002). This pattern was observed in 59% (82/
139) of histologically reviewed LumP tumors, although it
was frequently found in other luminal classes (42% in
LumNS and 31% in LumU). LumNS tumors were enriched in
micropapillary variant histology (36%, 9/25, p-adjusted =
0.032) and were commonly associated with carcinoma in
situ (80%, 4/5, p = 0.005).
A pathological review of stromal infiltration in slide
images corresponding to the TCGA tumor samples con-
firmed that stroma-rich tumors contained a higher propor-
tion of smooth muscle cells (p < 0.001), consistent with the
strong smooth muscle–related mRNA expression character-
izing these tumors.
3.5. Association of the consensus molecular classes with clinical
characteristics, survival outcomes, and therapeutic opportunities
The consensus classes were associated with gender, stage,
and age (Fig. 5A). Ba/Sq tumors were over-represented in
females (p < 0.001) and in higher clinical stages (p < 0.001),
consistent with published results [4,9–11]. The LumP and
LumU consensus classes were enriched in T2 versus T3–4
tumors (p = 0.009 and p < 0.001, respectively) as compared
with other classes. Younger patients (<60 yr) were over-
represented among LumP tumors (p = 0.001), whereas the
LumNS consensus class was enriched with older patients
(>80 yr; p = 0.03).
Overall survival was strongly associated with the
consensus classes (Fig. 5B, p < 0.001). The association of
consensus classes to survival was evaluated in a multivari-
able Cox model considering tumor stage, node, metastasis,
and patient age as covariates (p < 0.001; Supplementary
Table 6). The LumP class was used as the reference for class-
based survival. Patients with stroma-rich tumors had
similar outcomes to patients with LumP tumors
(HRStroma-rich/LumP = 0.98, IC95 = [0.65, 1.49]), and their sur-
vival was independent of the differentiation status of the
tumor sample (Supplementary Fig. 5). Likewise, patients
with LumNS tumors had similar prognosis to patients with
LumP tumors in this multivariable model, which considers
patient age (HRLumNS/LumP = 1.07; CI = [0.63, 1.82]).
The LumU class was associated with poorer patient
prognosis (HRLumU/LumP = 1.49, IC = [0.93, 2.39]), although in
this setting the difference was modest and not significant.
Ba/Sq tumors were associated with a poor prognosis
(HRBaSq/LumP = 1.83, IC = [1.30, 2.58], p < 0.001), consistentssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
Fig. 4 – Histopathological associations with consensus classes. (A) Histological variant over-representation within each consensus class. One-sided
Fisher exact tests were performed for each class and histological pattern; asterisks indicate a significant association between a consensus class and a
histological feature (p < 0.05). Pathological review of histological variants was available for several cohorts: squamous differentiation was evaluated in
CIT (n = 75), MDA (n = 46), Sjödahl2012 (n = 23), Sjödahl2017 (n = 239), and TCGA (n = 406) cohorts; neuroendocrine variants were reviewed in CIT (n =
75), MDA (n = 46), Sjödahl2017 (n = 243), and TCGA (n = 406) cohorts; micropapillary variants were reviewed in CIT (n = 75), MDA (n = 46), and TCGA
cohorts (n = 118 FFPE tumor slides from TCGA were reviewed by Y.A. and J.F. for this study). Results are displayed on the heatmap as –log10(adj Fisher’s
p). Detailed sample counts within each class are given in Supplementary Fig. 4. (B) Occurrence of papillary morphology in tumors from the TCGA
cohort (n = 401) and the CIT cohort (n = 47). (C) Proportion of samples with associated CIS within each consensus class in tumors from the CIT cohort
(n = 84) and the Dyrskjøt cohort (n = 8). (D) Smooth muscle infiltration from images for 173 tumor slides from the TCGA cohort. Each sample was
assigned a semiquantitative score ranging from 0 to 3 (0 = absent, 1 = low, 2 = moderate, and 3 = high) to quantify the presence of large smooth
muscle bundles. The bar plot shows means and standard errors for each class.
Ba/Sq = basal/squamous; CIS = carcinoma in situ; CIT = Cartes d’Identité des Tumeurs; FFPE = formalin-fixed paraffin-embedded; LumNS = luminal
nonspecified; LumP = luminal papillary; LumU = luminal unstable; MDA = MD Anderson Cancer Center; NE = neuroendocrine; TCGA = the Cancer Genome
Atlas.
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associated with the worst prognosis (HRNE-like/LumP = 2.34,
IC = [1.09, 5.05], p < 0.03).
We characterized the consensus classes using several
clinically relevant mRNA signatures (Fig. 5C and Supple-
mentary Table 7). The FGFR3 signature was strongly and
specifically activated in LumP tumors (p < 0.001), suggest-
ing that FGFR3-targeted therapies warrant investigation in
patients with tumors of this consensus class. Ba/Sq tumors
expressed high levels of EGFR and its ligands (p < 0.001),
which may be associated with sensitivity to EGFR-targeted
therapies, as suggested by previously reported in vitro and
in vivo experiments [11]. Ba/Sq tumors also strongly
expressed immune checkpoint markers (p < 0.001) and
antigen-presenting machinery genes (p < 0.001), suggest-
ing that such tumors might be more responsive to
immunotherapies. Studies integrating mRNA signatures
with data on response to anti-PD1/PD-L1 therapies [19,31]
have reported associations of anti-PD1/PD-L1 response with
high levels of CD8 + T cells, high interferon gamma signals,
and low activity of the transforming growth factor-beta
pathway. However, considering this combination of factors,Please cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006no consensus class had an expression profile that clearly
suggested either response or resistance to anti-PD1/PD-L1
therapies. In contrast, NE-like and LumU tumors both had
profiles associated with a potential response to radiothera-
py [32,33], showing elevated cell cycle activity (pNE-
like< 0.001 and pLumU< 0.001) and low hypoxia signals
(pNE-like = 0.01 and pLumU< 0.001).
Finally, we performed a consensus class–based retro-
spective analysis of outcomes of patients receiving neoad-
juvant chemotherapy (NAC) [12,18] and patients treated
with the anti-PD-L1 antibody atezolizumab (IMvigor210)
[19] (Supplementary Fig. 6). While outcome was associated
with the consensus class for NAC-free patients (Fig. 5B), for
NAC-treated patients, we observed no significant associa-
tion of outcome with the consensus class. Despite this,
comparison of survival curves with or without NAC
treatment (Supplementary Fig. 6A and Fig. 5B) suggested
that patients with Ba/Sq or LumNS tumors may benefit from
NAC, while patients with a stroma-rich tumor may not. We
observed an enrichment in atezolizumab responders among
patients with LumNS (p = 0.05), LumU (p = 0.0044), and NE-
like (p = 0.012) tumors. In particular, NE-like tumors mayssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
Fig. 5 – Clinical characteristics and prognostic associations. (A) Association of consensus classes with gender (n = 1554), clinical stage (n = 1641), and
age category (n = 1383). (B) Five-year overall survival stratified by consensus class (see also Supplementary Fig. 5). Kaplan-Meier curves were generated
from 872 patients with available follow-up data. Patients who had received neoadjuvant chemotherapy were excluded from the survival analysis.
Detailed statistics of the multivariable survival analyses is given in Supplementary Table 6. (C) We selected a set of clinically relevant gene signatures
(see Supplementary Table 7) and performed a gene set analysis (see the Supplementary material, Methods) in each dataset to test the significance of
their differential expression in each consensus class relative to the others. We used one-sided t tests to assess the differential expression of single
genes (PD-1 and PD-L1). The heatmaps show Stouffer combined p values over all datasets. Plus/minus annotation of gene sets indicates association of
high gene expression levels with response/resistance to the corresponding therapy.
Ba/Sq = basal/squamous; EGFR = epithelial growth factor receptor; FGFR = fibroblast growth factor receptor; IFN = interferon; LumNS = luminal
nonspecified; LumP = luminal papillary; LumU = luminal unstable; NE = neuroendocrine; TGF = transforming growth factor.
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recent results [34].
4. Discussion
While precision genomic medicine promises to transform
clinical practice, the diversity of published MIBC classifica-
tions has delayed transferring of subtypes into both clinicalPlease cite this article in press as: , et al. A Consensus Molecular Cla
https://doi.org/10.1016/j.eururo.2019.09.006trials and standard management of bladder cancer patients.
In the present study, we generated a stable consensus
classification system from existing well-documented mo-
lecular subtyping systems, following a procedure similar to
that used to identify consensus subtypes in colorectal
cancer [22]. The four consensus molecular subtypes
identified in that work have helped frame the development
of colorectal cancer precision medicine and are now being
evaluated in clinical trials [35,36].ssiﬁcation of Muscle-invasive Bladder Cancer. Eur Urol (2019),
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classification systems, based on 1750 MIBC transcriptomic
profiles. We identified six consensus MIBC molecular
classes that reconcile all six classification schemes: LumP,
LumU, stroma-rich, LumNS, Ba/Sq, and NE-like. Each
consensus class has distinct differentiation patterns,
oncogenic mechanisms, tumor microenvironments, and
histological and clinical associations, which are summa-
rized in Fig. 6. To facilitate translating the consensus classes
to research and clinical settings, we provide the community
with an R-based single-sample classifier that assigns a
consensus class label to a tumor sample’s transcriptome.
Some bladder tumors show histological and molecular
intratumor heterogeneity [37]. Our consensus subtyping
system addresses intertumor heterogeneity and focuses on
defining the main molecular subtypes of MIBC. Our
transcriptomic classifier will categorize tumors according
to the dominant class within the tumor sample analyzed.
We recognize that heterogeneous tumor samples may
contain multiple subtypes and that some tumor classes are
more clearly distinguishable from other tumor classes (eg,
Ba/Sq and NE-like tumors). We address how these
considerations are likely to interfere with our single-sample
classifier by having the classifier report not simply a class
label, but also correlation values to the centroids of the six
consensus classes, and a separation score that reflects how
well a sample is represented by its consensus class. FurtherFig. 6 – Summary of the main characteristics of the consensus classes. From to
consensus classes in the 1750 tumor samples; consensus class names; schemat
(immune cells, fibroblasts, and smooth muscle cells); differentiation-based col
luminal-to-basal gradient and neuroendocrine differentiation; and a table disp
mutations, stromal infiltrate, immune infiltrate, histology, clinical characterist
Ba/Sq = basal/squamous; LumNS = luminal nonspecified; LumP = luminal papilla
NE = neuroendocrine; NK = natural killer.
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heterogeneity on prognosis and response to treatment.
The consensus classification suggests possible therapeu-
tic implications. Both the high rate of FGFR3 mutations and
translocations in LumP tumors, and the FGFR3 activation
signatures [4,9] associated with these tumors suggest that
they may respond to fibroblast growth factor receptor
(FGFR) inhibitors, irrespective of the mutation or translo-
cation status of FGFR3. Novel FGFR inhibitors have been
reported to clinically benefit the 20% of MIBC patients
with tumors harboring mutations or translocations in the
tyrosine kinase receptor FGFR3 and the 40% of MIBC
patients with tumors overexpressing FGFR3 [38–40].
There is increasing interest in targeting the tumor
microenvironment, including the use of immunotherapy
strategies. In the USA and most of Europe, PD1 and PD-L1
immune checkpoint inhibition is becoming part of the
standard of care for patients with locally advanced or
metastatic urothelial cancer who relapse after cisplatin-
based chemotherapy or are considered cisplatin ineligible,
with a 20% objective response rate. A phase 3 clinical trial
has demonstrated the efficacy of targeting tumor vascula-
ture in MIBC using an anti-VEGFR2 inhibitor [41]. The
consensus classes are associated with different stromal
components, identified by transcriptomic signatures, and
likely different response to immunotherapy, as revealed by
our analysis of the IMvigor210 data, suggesting that theyp to bottom, the following characteristics are presented: proportion of
ic graphical representation of tumor cells and their microenvironments
or scale showing features associated with consensus classes, including a
laying the dominant characteristics such as oncogenic mechanisms,
ics, and median overall survival.
ry; LumU = luminal unstable; MIBC = muscle-invasive bladder cancer;
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immunotherapy or antiangiogenic therapy.
Similarities between MIBC consensus classes and other
cancer molecular subtypes reported in the PanCancer Atlas
work may also be considered for future basket trials. We
showed that such similarities are observed, for example,
between Ba/Sq MIBC tumors and squamous cell carcinomas
arising in the head and neck, lung, and cervix, which were
placed together in the C27 TCGA pan-cancer cluster. LumU
tumors and other ERBB2-amplified tumors in breast and
gastric cancers were also grouped together in the C2 pan-
cancer cluster. More generally, bladder cancer and breast
cancer luminal tumors share molecular similarities
[10,24]. Indeed, in both cancers, the luminal subtypes rely
on GATA3 and FOXA1, two transcription factors that are
necessary for luminal differentiation, and on a nuclear
receptor (the estrogen receptor (ESR1) in breast cancer or
PPARG in bladder cancer) [25]. Intriguingly, in both cancers,
there is evidence that the nuclear receptor is involved in
differentiation, while also having protumorigenic effects.
Such comparisons across tumor types may help transfer
treatment information from tumors bearing similar char-
acteristics to bladder cancer and vice versa.
The limitations of our study include cohorts that varied
in size, composition, and gene expression technology;
retrospective collection of clinical data; and incomplete
information regarding patient treatment. Validating our
findings, and refining subtype classification as an indepen-
dent predictor of response or prognosticator of outcome
will require prospective studies in which the proposed
classes are identified for patients who receive standardized
treatments.
5. Conclusions
We emphasize that we report biological rather than
clinical classes. We offer a single-sample mRNA classifier
(available in an R package and web application) as a
research tool for the retrospective and prospective work
required to establish how such classes can best be used
clinically. The consensus presented here provides a
common foundation for the molecular classification of
MIBC. Future substratifications may allow defining a
system that is more predictive of a response to treatments;
in such work, the clinical/strategic issue will be to decide
the subtype granularity or resolution [42] that is
appropriate for addressing a specific problem. We expect
that this consensus classification will help the develop-
ment of MIBC precision medicine by providing a robust
framework to connect clinical findings to molecular
contexts and to identify clinically relevant biomarkers
for patient management.
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